- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00245921
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
February 7, 2013 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception
To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
2000
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy women aged 18 to 49 years
- Regular (21- to 35- day) menstrual cycles for the 3-month period preceding visit 1
- Must be sexually active and at risk for becoming pregnant.
Exclusion Criteria:
- Planned use of any other form of birth control other than the test article.
- Depression requiring hospitalization or associated with suicidal ideation within the last 3 years.
- High blood pressure (defined as elevated sitting blood pressure: > 140/90 mm Hg).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To evaluate safety and contraceptive efficacy
|
Secondary Outcome Measures
Outcome Measure |
---|
To evaluate the effects of this LNG/EE combination on bleeding profile, endometrial histology, hemostasis measures, hemoglobin levels, discontinuation rates, subject satisfaction, and cycle-related symptoms and work productivity at baseline.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
October 1, 2005
Study Completion (Actual)
October 1, 2005
Study Registration Dates
First Submitted
October 26, 2005
First Submitted That Met QC Criteria
October 26, 2005
First Posted (Estimate)
October 28, 2005
Study Record Updates
Last Update Posted (Estimate)
February 8, 2013
Last Update Submitted That Met QC Criteria
February 7, 2013
Last Verified
May 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Levonorgestrel
- Estradiol
- Ethinyl Estradiol
Other Study ID Numbers
- 0858A2-313, 314, 320
- B3211019, B3211020, B3211022 (Other Identifier: Pfizer)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States
Clinical Trials on Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedOral Contraceptive
-
Laboratorios Andromaco S.A.Completed
-
Laboratorios Andromaco S.A.Completed
-
Laboratorios Andromaco S.A.CompletedTherapeutic EquivalencyIndia
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Regenex Pharmaceutical, ChinaUnknownOral ContraceptiveChina
-
University of CagliariUnknown
-
PfizerBoston Collaborative Drug Surveillance ProgramCompletedVenous Thrombosis | Pulmonary Embolism | Sinus Thrombosis, Intracranial
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Laboratorios Andromaco S.A.Completed